Repository Studies
Lay Title: GU Cancer Repository for Genitourinary Cancers
Technical Title: Data and Specimen Repository for Individuals with/at Risk for Genitourinary Cancers
Disease Type:
Patients with recently diagnosed genitourinary cancers (prostate, bladder, renal, testicular, adrenal, or penile cancers) and benign conditions such as renal cysts (fluid filled sacs in the kidney).
Basic information:
The purpose of this study is to construct a biologic specimen bank for research purposes.
This biologic specimen bank will study the genetic and biological factors contributing to the development of genitourinary cancers (prostate, bladder, renal, testicular, adrenal, or penile cancers) and benign conditions such as renal cysts (fluid filled sacs in the kidney). In the future, these specimens will be used for research on the study of cancer and benign conditions. Scientists will study the genes and the proteins that are found both in cancer and in normal tissue in hope it leads to improved clinical care in the future.
Research Procedures (not a complete list):
A portion of the material removed from patient’s body during standard clinical care will be retrieved, such as bodily fluids, blood, and tissue. Material requested can vary based on the type of material and the specific condition. The specimens will be stored in the biobank. In the future, these specimens will be used for research on the study of cancer and benign conditions in hope it would lead to improved clinical care.
Eligibility Criteria (Not a complete list):
Inclusion Criteria:
- Patients with a high risk of developing or currently having a diagnosis of a genitourinary cancer (such as prostate, bladder, renal, testicular, adrenal, or penile cancers)
Exclusion Criteria:
- Under 18 years old
- Unwilling or unable to provide informed consent
For More Detailed Information, Contact:
- Brian Shuch, MD, Principal Investigator
- Shirin Zavoshi, MD, (310) 794-9493
Lay Title: HLRCC Repository
Technical Title: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Data and Biospecimen Repository
Disease Type: Patients with a diagnosis of HLRCC as a result of 1) a genetic alteration in the fumarate hydratase (FH) gene or 2) have clinical features and a family history of an alteration in the FH gene.
Basic information:
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign tumors containing smooth muscle tissue (leiomyomas) in the skin and, in females, the uterus. This condition also increases the risk of kidney cancer.
The purpose of this study is to construct a biologic specimen bank for research purposes. Determining which additional factors contribute to the development of HLRCC manifestations, detecting biomarkers that may lead to earlier diagnosis, and learning more about the clinical outcomes with treatment strategies is the ultimate goal of the research. This biologic specimen bank will study the genetic and biological factors contributing to the development of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).
Research Procedures (not a complete list):
Patients with HLRCC can participate in our research to further our understanding of this condition. We will collect biospecimens, personal/family history, and clinical management on participants. This may include: 1) Intake questionnaire, 2) Medical records, 3) Archival or excess tissue, 4) Saliva sample, and 5) Blood Sample. Patients will not be required to come to UCLA. They can participate remotely as long as consent is obtained.
Eligibility Criteria (Not a complete list):
Inclusion Criteria:
- Patients given with a diagnosis of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Exclusion Criteria:
- Under 18 years old
- Unwilling or unable to provide informed consent
For More Detailed Information, Contact:
- Brian Shuch, MD, Principal Investigator
- Shirin Zavoshi, MD, (310) 794-9493